Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ15131MR)

This product GTTS-WQ15131MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases, Pemphigus vulgaris (PV) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Chimeric
RefSeq	NM_000484.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	351
UniProt ID	P05067

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15131MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ3194MR	IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	ARENEGYR
GTTS-WQ15933MR	IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ZTS-00084768
GTTS-WQ11967MR	IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MM-005
GTTS-WQ1509MR	IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ACE-011
GTTS-WQ12370MR	IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	N63Ab
GTTS-WQ14057MR	IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	REGN-3918
GTTS-WQ10774MR	IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	M-70
GTTS-WQ7178MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	FMC63 scFv-28Z CAR

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST